Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

- 18 décembre 2024 - 1 mn de lecture

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.

En rapport Clinical Trials

18 décembre 2024 1 mn de lecture

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

18 décembre 2024 1 mn de lecture

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

18 décembre 2024 1 mn de lecture

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

18 décembre 2024 1 mn de lecture

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

18 décembre 2024 1 mn de lecture

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

18 décembre 2024 1 mn de lecture

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

En rapport Clinical Trials

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

Dysport® Adult Lower Limb Spasticity Follow-on Study

Dysport® Pediatric Lower Limb Spasticity Study

Dysport® Adult Lower Limb Spasticity Study

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Dysport in the Treatment of Glabellar Lines in Chinese Subjects